DIRS.INFO The most relevant business & tech news

☆ Biogen raises full-year profit forecast on cost control
▼ + stars: | 2022-10-25 | by ( ) www.reuters.com time to read: +1 min

Oct 25 (Reuters) - Biogen Inc (BIIB.O) on Tuesday raised its full-year profit forecast for the second straight quarter, driven by its efforts to cut costs, while investors awaited more data on its new Alzheimer's disease drug next month. The focus of investors as well as Wall Street is squarely on Biogen and Eisai Co Ltd's (4523.T) new drug lecanemab that slowed the progress of the disease by 27% in a trial last month. read moreThe company raised its full-year adjusted earnings per share forecast to between $16.50 and $17.15 from $15.25 to $16.75 previously. Investors have been pinning hopes on the new Alzheimer's disease drug as Biogen faces multiple setbacks including competition for blockbuster drug Tecfidera and a failed launch of Aduhelm, its earlier Alzheimer's drug. Register now for FREE unlimited access to Reuters.com RegisterReporting by Manas Mishra and Bhanvi Satija in Bengaluru; Editing by Arun KoyyurOur Standards: The Thomson Reuters Trust Principles.

☆ Biogen sales fall 9.7% on Tecifdera competition
▼ + stars: | 2022-10-25 | by ( ) www.reuters.com time to read: 1 min

Oct 25 (Reuters) - Biogen Inc (BIIB.O) reported a 9.7% drop in quarterly sales on Tuesday due to rising competition for its blockbuster multiple sclerosis drug Tecfidera, while investors awaited more data on its new Alzheimer's disease drug next month. The focus of investors as well as Wall Street is squarely on Biogen and Eisai Co Ltd's (4523.T) new drug lecanemab that slowed progress of the disease by 27% in a trial last month. read moreRegister now for FREE unlimited access to Reuters.com RegisterReporting by Manas Mishra and Bhanvi Satija in Bengaluru; Editing by Arun KoyyurOur Standards: The Thomson Reuters Trust Principles.

☆ Global COVID cases will increase in coming months, but at a slower pace, analysis says
▼ + stars: | 2022-10-25 | by ( ) www.reuters.com time to read: +2 min

Oct 25 (Reuters) - Daily global COVID-19 infections are projected to rise slowly to about 18.7 million by February from the current 16.7 million aveage daily cases, driven by the northern hemisphere's winter months, the University of Washington said in an analysis. The increase in cases is not expected to cause a surge in deaths, the University of Washington's Institute for Health Metrics and Evaluation (IHME) said. It forecast that global daily deaths would average 2,748 people on Feb. 1, compared with around 1,660 currently. IHME estimates that daily infections in the United States will increase by a third to more than a million, driven by students back in schools and cold weather-related indoor gatherings. A rapid increase in hospital admissions in Germany – the highest since the COVID outbreak in 2020 - remains an area of concern, it said.

☆ Global COVID cases will increase in coming months, but at a slower pace -report
▼ + stars: | 2022-10-25 | by ( ) www.reuters.com time to read: +2 min

Oct 25 (Reuters) - Daily global COVID-19 infections are projected to rise slowly to about 18.7 million by February from the current 16.7 million aveage daily cases, driven by the northern hemisphere's winter months, the University of Washington said in an analysis. The increase in cases is not expected to cause a surge in deaths, the University of Washington's Institute for Health Metrics and Evaluation (IHME) said. It forecast that global daily deaths would average 2,748 people on Feb. 1, compared with around 1,660 currently. A surge in Germany has peaked already, it said in its report on Oct. 24. A rapid increase in hospital admissions in Germany – the highest since the COVID outbreak in 2020 - remains an area of concern, it said.

☆ Abbott raises 2022 profit forecast for second time
▼ + stars: | 2022-10-19 | by ( Nancy Lapid | ) www.reuters.com time to read: +1 min

Oct 19 (Reuters) - Abbott Laboratories (ABT.N) on Wednesday raised its annual earnings forecast for the second time, citing strong demand for medical devices and COVID-19 diagnostic tests. COVID-19 test kit sales were up $1.7 billion, compared to $1.9 billion last year and $2.3 billion in the second quarter, as testing declined amid a slower pace of infections. The company now expects $5.17-$5.23 per share in adjusted earnings this year, compared to at least $4.90 per share it forecast earlier. read moreAbbott said it expects around $7.8 billion in COVID-19 test sales this year, with $500 million in the fourth quarter, compared to the $6.1 billion it had forecast earlier. The Illinois-based company reported third-quarter worldwide sales of $10.4 billion, down 4.7% from a year ago.

☆ Google approves Trump's Truth Social for Play Store
▼ + stars: | 2022-10-12 | by ( Helen Coster | ) www.reuters.com time to read: +1 min

Oct 12 (Reuters) - Alphabet Inc's (GOOGL.O) Google has approved former U.S. President Donald Trump's social media app Truth Social for distribution in the Google Play Store, a company spokesperson said on Wednesday. Trump Media & Technology Group (TMTG), which operates Truth Social, is expected to make the app available in the Google Play Store shortly, Google said. Truth Social, which launched in the United States in the Apple App Store in February, had not previously been available in the Google Play Store due to insufficient content moderation, according to a Google spokesperson in August. Register now for FREE unlimited access to Reuters.com RegisterWithout the Google and Apple stores, there is no easy way for most smartphone users to download Truth Social. Truth Social restored Trump's presence on social media more than a year after he was banned from Twitter Inc (TWTR.N), Facebook (META.O) and Alphabet Inc's YouTube following the Jan. 6, 2021 U.S. Capitol riots, after he was accused of posting messages inciting violence.

☆ U.S. FDA warns of ADHD drug Adderall shortage on Teva manufacturing delays
▼ + stars: | 2022-10-12 | by ( ) www.reuters.com time to read: +1 min

Oct 12 (Reuters) - The U.S. Food and Drug Administration said on Wednesday there was a shortage of Adderall, a treatment for attention deficit hyperactivity disorder, following intermittent manufacturing delays at Teva Pharmaceutical Industries Ltd (TEVA.TA). Adderall is an FDA-approved prescription drug made of two stimulants amphetamine and dextroamphetamine. According to the FDA's website, supply recovery for different doses and forms of the drug ranges from October 2022 to March 2023. The company will continue to have challenges supplying Adderall for the next two to three months, Bloomberg News reported last week. Register now for FREE unlimited access to Reuters.com RegisterReporting by Bhanvi Satija in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.

☆ Diagnostics firm Bio-Rad in talks to merge with Qiagen - WSJ
▼ + stars: | 2022-10-10 | by ( ) www.reuters.com time to read: +1 min

Oct 10 (Reuters) - California-based diagnostics company Bio-Rad Laboratories (BIO.N) is in talks to merge with Qiagen NV (QIA.DE), the Wall Street Journal reported on Monday, citing people familiar with the matter. U.S-listed shares of Qiagen rose 8% while Bio-Rad fell nearly 10% after the report. Register now for FREE unlimited access to Reuters.com RegisterBio Rad, which manufactures and supplies products such as laboratory apparatus, instruments and diagnostics, has a market-cap of $12.85 billion. Both Qiagen and Bio-Rad did not immediately respond to Reuters' requests for comments. Register now for FREE unlimited access to Reuters.com RegisterReporting by Bhanvi Satija in Bengaluru; Editing by Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.

☆ Workiva gets takeover interest from Thoma Bravo, TPG - Bloomberg News
▼ + stars: | 2022-09-28 | by ( ) www.reuters.com time to read: +1 min

Sept 28 (Reuters) - Cloud-based data platform Workiva (WK.N) has received takeover interest from private equity firms Thoma Bravo and TPG (TPG.O), Bloomberg News reported on Wednesday citing sources familiar with the matter. Private equity firms have taken several software companies including Anaplan and Zendesk Inc private this year. Thoma Bravo this year has acquired cybersecurity firm SailPoint, agreed to buy Ping Identity Holding (PING.N) and has expressed interest in British firm Darktrace Plc (DARK.L) and Australia's Nearmap (NEA.AX). Workiva, which currently has a market value of $3.4 billion, told Reuters it would not comment on market rumors and speculation. Thoma Bravo and TPG did not immediately respond to a Reuters request for comment.

☆ U.S. FDA clears additional lots of Moderna's Covid booster amid shortage
▼ + stars: | 2022-09-26 | by ( ) www.reuters.com time to read: +1 min

A healthcare worker holds a vial of the Moderna COVID-19 Vaccine at a pop-up vaccination site operated by SOMOS Community Care during the coronavirus disease (COVID-19) pandemic in Manhattan in New York City, New York, U.S., January 29, 2021. REUTERS/Mike Segar/File PhotoSept 26 (Reuters) - The U.S. Food and Drug Administration said on Monday it has authorized an additional five batches of Moderna Inc's (MRNA.O) updated Covid booster shots made at a Catalent facility in Indiana, after it deemed them safe for use. Last week, the health regulator had allowed use of ten batches of Moderna's updated booster shots made at the Bloomington, Indiana facility, owned by a unit of Catalent Inc (CTLT.N), which is currently not a part of the company's emergency use authorization. The FDA had earlier said Moderna had requested authorization for additional batches in light of the current supply issues. The U.S. government, which has sent out over 25 million of the COVID-19 booster shots targeting BA.4 and BA.5 subvariants of Omicron, has ordered more than 170 million updated shots for this fall, in preparation for a broad revaccination campaign.

Search resuls for: "Bhanvi Satija"

10 mentions found